

HISTORICALLY ACCEPTED USE

Tertiary and Quaternary Committee

Executive Summary

<p>Date: May 2022</p> <p>Medicine (INN): Dithranol</p> <p>Medicine (ATC): D05AC01</p> <p>Indication (ICD10 code): Psoriasis (L40.9)</p> <p>Patient population: Patients with local psoriasis plaques</p> <p>Prevalence of condition: Prevalence of psoriasis in various countries ranges from 0.09% to 11.43%.¹ African and Asian populations have a lower frequency of between 0.4% and 0.7%.²</p> <p>Level of Care: Tertiary and Quaternary</p> <p>Prescriber Level: Dermatologist</p> <p>Current standard of Care: Hospital level – coal tar ointment and topical corticosteroids for flares.</p> <p>Efficacy estimates:</p> <ul style="list-style-type: none"> Dithranol has been shown to be effective in the treatment of mild to moderate psoriasis.³ <i>(Recommendation based on inconsistent or limited quality patient-oriented evidence)</i> Alternative topical agents such as coal tar (recommended for mild to moderate psoriasis - <i>Recommendation based on consistent and good quality patient-oriented evidence</i>) and topical corticosteroids have stronger recommendations.

<p>Background</p> <p>This agent was previously included in the Adult Hospital Level Standard Treatment Guideline and Essential Medicines List, 2006 version; for treatment of local plaques, specialist initiated</p>

Historically accepted use Criteria

Criteria		Comment	
1	The medicine is included in the WHO Model Essential Medicines List, either as a core or complementary item, for the indication requested.	YES <input type="checkbox"/>	NO <input checked="" type="checkbox"/>
		<i>Coal tar and corticosteroids listed under dermatological medicine. No specific psoriasis treatment outlined.</i>	
2	The medicine is currently registered by SAHPRA for the indication.	YES <input type="checkbox"/>	NO <input checked="" type="checkbox"/>
3	There is evidence of long-established (prior to 1996*) safe and effective use of the medicine for the recognised indication in the public health sector.	YES <input checked="" type="checkbox"/>	NO <input type="checkbox"/>
		Comment:	
4	New safety or efficacy concerns.	YES <input type="checkbox"/>	NO <input checked="" type="checkbox"/>
		Comment:	

5	Budget impact is <u>not</u> expected to have an incremental increase, that a de novo review is justified.	<table border="1" style="width: 100%; text-align: center;"> <tr> <td style="width: 50%;">YES</td> <td style="width: 50%;">NO</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </table> <p>No local price</p>	YES	NO	<input type="checkbox"/>	<input type="checkbox"/>
YES	NO					
<input type="checkbox"/>	<input type="checkbox"/>					
6	Equitable access across the country is essential, and is limited only by the availability of adequately trained staff and availability of equipment.	<table border="1" style="width: 100%; text-align: center;"> <tr> <td style="width: 50%;">YES</td> <td style="width: 50%;">NO</td> </tr> <tr> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/> X</td> </tr> </table> <p>Comment: would only be available through section 21</p>	YES	NO	<input type="checkbox"/>	<input checked="" type="checkbox"/> X
YES	NO					
<input type="checkbox"/>	<input checked="" type="checkbox"/> X					

* The Essential Drugs Programme (EDP) of South Africa was established in terms of the National Drug Policy (NDP) which was implemented in 1996

Recommendation

Dithranol is not recommended for inclusion on the Tertiary and Quaternary Essential Medicines List. It is currently not registered in South Africa and it does not provide any superior benefit to currently available therapies.

REFERENCES

¹ World Health Organisation. Global report on Psoriasis. WHO Library, 2016.
https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf.psoriasis;jsessionid=54912784D28C9F36ECCD45471AC5775B?sequence=1

² Engler D, Chezuba HP, Masuku P. Psoriasis – Review. South African Pharmacy Journal. 2017, 84(5):38-42.

³ Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et.al. Joint ADD-NPF Guideline for care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 2021;84:432-70.